Abstract
Deregulation of apoptosis has been shown to contribute to the development of many diseases, including ischemia/ reperfusion injury of organs, different types of cancer formation, as well as neurodegenerative and autoimmune disorders. Recently, the mitochondrial serine protease High temperature requirement A2 (HtrA2)/Omi has drawn attention as it played pivotal role in different pathological conditions. We critically discussed the rationale for therapeutically targeting HtrA2 signaling in pathological conditions and explore the molecular mechanisms of HtrA2 inhibition as a novel therapeutic strategy. The precise mode of action and importance of HtrA2 in mitochondrial quality control as well as in apoptosis in mammalian cells has been recently studied through biochemical, structural and genetic studies. This review introduces HrtA2 from its molecular origins, discusses its modulation and potential as a novel drug target, and considers future therapeutic perspectives.
Keywords: HtrA2, apoptosis, mitochondria, inhibitor of apoptosis proteins, caspases
Current Drug Targets
Title: Mitochondrial Serine Protease HtrA2/Omi as a Potential Therapeutic Target
Volume: 10 Issue: 4
Author(s): Md. Shenuarin Bhuiyan and Kohji Fukunaga
Affiliation:
Keywords: HtrA2, apoptosis, mitochondria, inhibitor of apoptosis proteins, caspases
Abstract: Deregulation of apoptosis has been shown to contribute to the development of many diseases, including ischemia/ reperfusion injury of organs, different types of cancer formation, as well as neurodegenerative and autoimmune disorders. Recently, the mitochondrial serine protease High temperature requirement A2 (HtrA2)/Omi has drawn attention as it played pivotal role in different pathological conditions. We critically discussed the rationale for therapeutically targeting HtrA2 signaling in pathological conditions and explore the molecular mechanisms of HtrA2 inhibition as a novel therapeutic strategy. The precise mode of action and importance of HtrA2 in mitochondrial quality control as well as in apoptosis in mammalian cells has been recently studied through biochemical, structural and genetic studies. This review introduces HrtA2 from its molecular origins, discusses its modulation and potential as a novel drug target, and considers future therapeutic perspectives.
Export Options
About this article
Cite this article as:
Bhuiyan Shenuarin Md. and Fukunaga Kohji, Mitochondrial Serine Protease HtrA2/Omi as a Potential Therapeutic Target, Current Drug Targets 2009; 10 (4) . https://dx.doi.org/10.2174/138945009787846399
DOI https://dx.doi.org/10.2174/138945009787846399 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroprotection of (+)-2-(1-Hydroxyl-4-Oxocyclohexyl) Ethyl Caffeate Against Hydrogen Peroxide and Lipopolysaccharide Induced Injury via Modulating Arachidonic Acid Network and p38-MAPK Signaling
Current Alzheimer Research Heat Shock Proteins Protect Against Ischemia and Inflammation Through Multiple Mechanisms
Inflammation & Allergy - Drug Targets (Discontinued) Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Effectors of Fatty Acid Oxidation Reduction: Promising New Anti-Ischaemic Agents
Current Pharmaceutical Design Benzopyran Derivatives as Cardio-selective ATP-sensitive Potassium Channel Openers: A Review
Mini-Reviews in Medicinal Chemistry From Erythropoietin to Its Peptide Derivatives: Smaller but Stronger
Current Protein & Peptide Science DNAzyme Delivery Approaches in Biological Settings
Current Medicinal Chemistry Dual COX Inhibition and Upper Gastrointestinal Damage
Current Pharmaceutical Design Mechanisms of the Beneficial Actions of Ischemic Preconditioning on Subcellular Remodeling in Ischemic-Reperfused Heart
Current Cardiology Reviews Role of Innate Immune System in Inflammation and Cardiac Remodeling After Myocardial Infarction
Current Vascular Pharmacology Mitochondrial Signaling and Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Implications
Current Pharmaceutical Design Postischemic-Anoxic Encephalopathy After Global Forebrain Ischemia
Central Nervous System Agents in Medicinal Chemistry Effect of Glycine on Adipocyte Hypertrophy in a Metabolic Syndrome Rat Model
Current Drug Delivery Cell Therapy for the Treatment of Chronic Ischemic Heart Disease
Current Pharmaceutical Design Prostacyclin Synthase Gene: Implication and Prevention of Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Advances in Characterization of Neuroprotective Peptide, Humanin
Current Medicinal Chemistry Platelets in Angiogenesis
Current Vascular Pharmacology Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Adrenomedullin in Hypertension
Current Hypertension Reviews Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Mechanical Intervention for Acute Myocardial Infarction
Current Medicinal Chemistry - Cardiovascular & Hematological Agents